Registry / 2023

Retatrutide Phase 2 obesity study

Retatrutide Phase 2 obesity study — ClinicalTrials.gov (2023), cited in PeptideAgent's Retatrutide evidence record.

Open original source

SOURCE METADATA

What this record represents.

Publisher
ClinicalTrials.gov
Evidence type
Registry
Publication year
2023
Source ID
nct04881760

WHERE THIS IS CITED

Connected evidence records.

RetatrutidePeptide analog · Weight & Metabolism